From January 9th to 10th, the inaugural Songshan Lake Forum: In Vivo CAR-T Special Symposium, co-hosted by Guangdong San-Sheng Pharmaceutical Co., Ltd. and Jiangsu Shenji Biotechnology Co., Ltd., was successfully held in Dongguan, Guangdong. The forum gathered top global scientists, leaders from cutting-edge biotechnology enterprises, seasoned industry chain partners, and policymakers. Participants focused on the forefront of in vivo CAR-T technology and its industrialization pathways, discussing the future development of the industry. Professor Wang Jianxun, Chief Scientist of Cell Valley Group, was invited to attend and delivered a keynote speech.

The Songshan Lake Forum, established with strong support from all sectors of Songshan Lake, is the inaugural high-end industrial dialogue platform integrating "government, industry, academia, research, and application." It has been designated as an annual flagship event. With its permanent venue located at Guangdong San-Sheng, the forum aims to root itself in Songshan Lake, integrate into the Greater Bay Area, and connect with the world, fostering an open, collaborative, and win-win ecosystem for the Cell and Gene Therapy (CGT) sector.Currently, in vivo CAR-T therapy is leading the next generation of cell treatment revolution. Due to advantages such as rapid and simplified manufacturing processes and lower costs, it has become a core exploration direction during the critical window period for transitioning from concept to clinic in 2026. The timing of this special symposium is therefore highly opportune, building a vital bridge for industry exchange and cooperation.

On the morning of the 10th, Professor Wang Jianxun, Chief Scientist of Cell Valley Group, delivered a keynote speech at the forum titled 《Efficient Gene Editing Systems Mediated by Virus-Like Particles Empowering In Vivo CAR-T Cell Products》. This technology was previously featured in a significant paper published in the prestigious international journal 《Molecular Therapy》, co-authored with Nobel Laureate Professor Mario Capecchi and others.He provided an in-depth interpretation of how in vivo CAR-T, as a disruptive technology in the field of cellular and gene therapy, breaks through the industry bottleneck of traditional CAR-T therapy—complex procedures and high costs—by adopting an innovative approach that eliminates the need for extracorporeal cell collection and expansion. Professor Jianxun Wang elaborated on the advantages of the eVLP system over conventional techniques, including high delivery efficiency, low off-target risk, and no risk of DNA integration. Moreover, a single intravenous injection can complete the treatment, avoiding the complex steps of patient T-cell collection and extracorporeal expansion. He cited data demonstrating that eVLP technology exhibited durable antitumor activity in mouse models, significantly enhanced CAR-T cell expansion, and optimized cytokine release. This provides a more convenient and safer novel solution for the treatment of hematologic malignancies and solid tumors. He emphasized that, driven by both policy support and technological advancements, in vivo CAR-T is reshaping the landscape of tumor immunotherapy with its breakthrough advantage of "a single intravenous injection for complete treatment," offering new hope for global patients. The cutting-edge technical concepts and robust clinical data garnered widespread attention and high recognition from the audience.

The successful hosting of the inaugural Songshan Lake Forum's in vivo CAR-T symposium has established an efficient platform for industry collaboration, accelerating technological innovation and resource integration in the field of in vivo CAR-T therapy.Shenzhen Cell Valley Group stated that it will continue to delve deeply into the core technology research and development of Cell and Gene Therapy (CGT). Committed to active participation in collaborative industry innovation, the group will leverage its technical advantages and R&D capabilities to facilitate the realization of more innovative technologies and products. Ultimately, Cell Valley aims to contribute to advancing disease treatment standards and benefiting a broader patient population.